Methyl 2-Oxoindoline-6-Carboxylate CAS 14192-22-8 Puritas >99.0% (HPLC) Nintedanib Esylate Factory Featured Image

Methyl 2-Oxoindoline-6-Carboxylate CAS 14192-22-8 Puritas >99.0% (HPLC) Nintedanib Esylate Factory intermedia

Description:

Nomen chemicum: Methyl 2-Oxoindoline-6-Carboxylate

CAS: 14192-26-8

Puritas: >99.0% (HPLC)

Aspectus: Lumen Yellow ad Brown pulveris

Intermedia Nintedanib Esylate (CAS: 656247-18-6) in curatione cancri pulmonis non minimi & fibrosis pulmonis idiopathici

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Shanghai Ruifu Chemical Co., Ltd. est primarius fabricae et supplementi Methyl 2-Oxoindolini-6-Carboxylati (CAS: 14192-26-8) magna cum qualitate, productio commercialis.

Chemical Properties:

Nomen chemicum	Methyl 2-Oxoindoline-6-Carboxylatus
Synonyma	2-Oxoindoline-6-Carboxylic Acidum Methyl Ester;Methyl Oxindole-6-Carboxylata
CAS Number	14192-26-8
CATTUS Number	RF-PI1524
Stock Status	In Stock, Productio Ascendite ad Tons
Formulae hypotheticae	C10H9NO3
M. Pondus	191.19
Liquescens punctum	184.0~190.0℃
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Lux Yellow ut Brown pulveris
1 H NMR Spectrum	Congruunt cum Structure
Puritas / Analysis Methodus	>99.0% (HPLC)
Damnum in Siccatio	<1.00%
Totalis immunditias	<1.00%
Test Standard	Enterprise Standard
Consuetudinem	Intermedia Nintedanib Esylate (CAS: 656247-18-6)

Methyl 2-Oxoindoline-6-Carboxylatus (CAS: 14192-22-8) Synthetica Route

Sarcina & Repono:

sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris.

Repono Condition:Repone in vasis signatis in loco frigido et sicco;A luce et humore protege.

commoda:

FAQ:

Applicatio:

Methyl 2-Oxoindoline-6-Carboxylatus (CAS: 14192-26-8) media usus est ad parandum Nintedanib Esylate (CAS: 656247-18-6).Nintedanib Esylate inhibitor angiokinasi triplex potens, oralis a Boehringer Ingelheim evoluta est, qui scopos proangiogenicos et pro-fibroticos per vias endotheliales vasculares mediatas incrementi factoris receptoris, fibroblastae aucti factoris receptoris et aucti factoris receptae familiae, necnon Src et Flt-3 kinases.Nintedanib Esylate probata est pro curatione fibrosis pulmonis idiopathicae (IPF), condicio qua paulatim cicatrices per tempus fiunt, ab US FDA mense Octobre 2014 et ab EMA mense Ianuario 2015. FDA nintedanib esylate ieiunii semita concessit. recensio prioritas, pupillus productus et designationes breakthrough.Hoc etiam ab EMA mense Novembri 2014 probatum est propter curationem cancri cellulae non parvae coniuncte cum docetaxel post primam aciem chemotherapyam.